Roche failure likely worst case for Arcus study, says Cantor Fitzgerald
PremiumThe FlyRoche failure likely worst case for Arcus study, says Cantor Fitzgerald
20d ago
Arcus Biosciences price target lowered to $44 from $50 at Truist
PremiumThe Fly
Arcus Biosciences price target lowered to $44 from $50 at Truist
1M ago
Arcus completes enrollment for domvanalimab study for GI cancer
PremiumThe Fly
Arcus completes enrollment for domvanalimab study for GI cancer
2M ago
Arcus Biosciences reports Q1 EPS (5c), consensus (95c)
PremiumThe FlyArcus Biosciences reports Q1 EPS (5c), consensus (95c)
3M ago
Arcus Biosciences price target lowered to $37 from $44 at Citi
PremiumThe Fly
Arcus Biosciences price target lowered to $37 from $44 at Citi
3M ago
Arcus Biosciences reports Q4 EPS ($1.08), consensus ($1.02)
PremiumThe Fly
Arcus Biosciences reports Q4 EPS ($1.08), consensus ($1.02)
5M ago
Arcus Biosciences Sells Equity to Gilead Under Section 4(a)(2)
PremiumCompany AnnouncementsArcus Biosciences Sells Equity to Gilead Under Section 4(a)(2)
6M ago
Arcus Biosciences Enhances Partnership with Gilead Sciences
PremiumCompany Announcements
Arcus Biosciences Enhances Partnership with Gilead Sciences
6M ago
Arcus Biosciences price target lowered to $30 from $36 at Wedbush
PremiumThe Fly
Arcus Biosciences price target lowered to $30 from $36 at Wedbush
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100